lilly retatrutide trial Eli infiltrates anti-obesity market as Phase III for begins Retatrutide, Eli Lilly's next obesity

In addition to its pharmacological benefits, retatrutide is part of a broader lifestyle intervention strategy that includes dietary changes and increased physical activity

For the majority of GLP-1 users, digestive symptoms are part of what researchers describe as a gut adaptation phase

Having hypothyroidism does not make these medications less effective or more dangerous when thyroid hormone levels are appropriately managed with levothyroxine

Published by the iPharma Research Team Medically reviewed by PCCA- and NHIA-certified compounding pharmacists with 27+ years of clinical experience in sterile compounding, GLP-1 therapy, and personalized medicine Last reviewed July 2026 Educational information only

Heres what you can expect: Wegovy : People taking Wegovy lost an average of 15% of their body weight over 68 weeks

those who responded that they did not know were counted as not having the condition